Achinoam Faust-Socher1,2, Sarah Duff-Canning1, Arthur Grabovsky3, Melissa J Armstrong4, Brandon Rothberg1, Paul J Eslinger5, Christopher A Meaney6, Ruth B Schneider7, David F Tang-Wai8, Susan H Fox1, Cindy Zadikoff9, Nancy Kennedy10, Kelvin L Chou11, Carol Persad12, Irene Litvan13, Benjamin T Mast14, Adam T Gerstenecker15, Sandra Weintraub16, William Reginold1, Connie Marras17. 1. The Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada. 2. Movement Disorders Unit, Tel Aviv Medical Center, Tel Aviv, Israel. 3. Department of Statistical Sciences, University of Toronto, Toronto, Ontario, Canada. 4. Department of Neurology, University of Florida College of Medicine, Gainesville, Florida, USA. 5. Departments of Neurology, Neural and Behavioral Sciences, and Radiology, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. 6. Division of Biostatistics, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. 7. Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA. 8. Division of Neurology, University Health Network Memory Clinic, University of Toronto, Toronto, Ontario, Canada. 9. Department of Neurology, Northwestern University, Chicago, Illinois, USA. 10. Department of Psychiatry and Behavioral Science, Northwestern University, Chicago, Illinois, USA. 11. Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA. 12. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA. 13. Parkinson and Other Movement Disorders Center, Department of Neuroscience, UC San Diego, San Diego, California, USA. 14. Psychological and Brain Sciences, University of Louisville, Louisville, Kentucky, USA. 15. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 16. Department of Psychiatry and Behavioural Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 17. The Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada, connie.marras@utoronto.ca.
Abstract
BACKGROUND: Clinical monitoring of patients with Parkinson's disease (PD) for cognitive decline is an important element of care. The Montreal Cognitive Assessment (MoCA) has been proposed to be a sensitive tool for assessing cognitive impairment in PD. The aim of our study was to compare the responsiveness of the MoCA to decline in cognition to the responsiveness of the Mini Mental State Examination (MMSE) and the Scales for Outcomes of Parkinson's disease-cognition (SCOPA-Cog). METHODS: PD patients without dementia were enrolled at 6 North American movement disorders centers between 2008 and 2011. Participants received annual evaluations including the MoCA, MMSE, and SCOPA-Cog followed by formal neuropsychological testing. The gold standard for change in cognition was defined as the change on the neuropsychological test scores over the annual assessments. The Reliable Change Method was used to provide an estimate of the probability that a given difference score would be obtained by chance. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change was quantified using receiver operating characteristics (ROC) curves. RESULTS: One hundred seventeen patients were included in the analysis. Participants were followed at mean intervals of 11 ± 2 months for a median of 2 (maximum 5) visits. According to the reliable change index, 56 intervals of cognitive testing showed a decline in global cognition. ROC analysis of change in MoCA, MMSE, and SCOPA-Cog global scores compared to gold standard testing found an area under the curve (AUC) of 0.55 (95% CI 0.48-0.62), 0.56 (0.48-0.63), and 0.63 (0.55-0.70) respectively. There were no significant differences in the AUCs across the tests. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change at various thresholds for decline in scores reached a maximum of 71% for a cut-off of 1 point change on the SCOPA-Cog. CONCLUSION: Using neuropsychological testing as a gold standard comparator, the performance of the MoCA, MMSE, and SCOPA-Cog for detecting decline in non-demented PD patients over a 1-year interval is poor. This has implications for clinical practice; stable scores may not be taken as reassurance of the absence of cognitive decline.
BACKGROUND: Clinical monitoring of patients with Parkinson's disease (PD) for cognitive decline is an important element of care. The Montreal Cognitive Assessment (MoCA) has been proposed to be a sensitive tool for assessing cognitive impairment in PD. The aim of our study was to compare the responsiveness of the MoCA to decline in cognition to the responsiveness of the Mini Mental State Examination (MMSE) and the Scales for Outcomes of Parkinson's disease-cognition (SCOPA-Cog). METHODS:PDpatients without dementia were enrolled at 6 North American movement disorders centers between 2008 and 2011. Participants received annual evaluations including the MoCA, MMSE, and SCOPA-Cog followed by formal neuropsychological testing. The gold standard for change in cognition was defined as the change on the neuropsychological test scores over the annual assessments. The Reliable Change Method was used to provide an estimate of the probability that a given difference score would be obtained by chance. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change was quantified using receiver operating characteristics (ROC) curves. RESULTS: One hundred seventeen patients were included in the analysis. Participants were followed at mean intervals of 11 ± 2 months for a median of 2 (maximum 5) visits. According to the reliable change index, 56 intervals of cognitive testing showed a decline in global cognition. ROC analysis of change in MoCA, MMSE, and SCOPA-Cog global scores compared to gold standard testing found an area under the curve (AUC) of 0.55 (95% CI 0.48-0.62), 0.56 (0.48-0.63), and 0.63 (0.55-0.70) respectively. There were no significant differences in the AUCs across the tests. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change at various thresholds for decline in scores reached a maximum of 71% for a cut-off of 1 point change on the SCOPA-Cog. CONCLUSION: Using neuropsychological testing as a gold standard comparator, the performance of the MoCA, MMSE, and SCOPA-Cog for detecting decline in non-demented PDpatients over a 1-year interval is poor. This has implications for clinical practice; stable scores may not be taken as reassurance of the absence of cognitive decline.
Authors: William M McDonald; Paul E Holtzheimer; Michael Haber; Jerrold L Vitek; Kimberly McWhorter; Mahlon Delong Journal: Mov Disord Date: 2006-10 Impact factor: 10.338
Authors: V Isella; C Mapelli; N Morielli; C Siri; D De Gaspari; G Pezzoli; A Antonini; M Poletti; U Bonuccelli; L Picchi; A Napolitano; M Vista; I M Appollonio Journal: Parkinsonism Relat Disord Date: 2013-08-22 Impact factor: 4.891
Authors: Robert Perneczky; Alexander Drzezga; Henning Boecker; Andres O Ceballos-Baumann; Oliver Granert; Hans Förstl; Alexander Kurz; Peter Häussermann Journal: Dement Geriatr Cogn Disord Date: 2008-11-04 Impact factor: 2.959
Authors: Michele T M Hu; Konrad Szewczyk-Królikowski; Paul Tomlinson; Kannan Nithi; Michal Rolinski; Clara Murray; Kevin Talbot; Klaus P Ebmeier; Clare E Mackay; Yoav Ben-Shlomo Journal: Mov Disord Date: 2014-01-06 Impact factor: 10.338
Authors: Matej Skorvanek; Jennifer G Goldman; Marjan Jahanshahi; Connie Marras; Irena Rektorova; Ben Schmand; Erik van Duijn; Christopher G Goetz; Daniel Weintraub; Glenn T Stebbins; Pablo Martinez-Martin Journal: Mov Disord Date: 2017-11-23 Impact factor: 10.338
Authors: Rachael A Lawson; Alison J Yarnall; Gordon W Duncan; David P Breen; Tien K Khoo; Caroline H Williams-Gray; Roger A Barker; Daniel Collerton; John-Paul Taylor; David J Burn Journal: Parkinsonism Relat Disord Date: 2016-04-11 Impact factor: 4.891
Authors: Eileen Gülke; Mohammad Alsalem; Maja Kirsten; Eik Vettorazzi; Chi-Un Choe; Ute Hidding; Simone Zittel-Dirks; Carsten Buhmann; Miriam Schaper; Alessandro Gulberti; Christian K E Moll; Wolfgang Hamel; Johannes Koeppen; Christian Gerloff; Monika Pötter-Nerger Journal: PLoS One Date: 2022-04-07 Impact factor: 3.240